In patients with COVID-19 receiving IMV or ECMO, adding baricitinib to usual care reduced all-cause mortality.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 35667076.
- Also identified by DOI 10.7326/J22-0033.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ely EW, Ramanan AV, Kartman CE, et al. <b>Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.</b> Lancet Respir Med. 2022;10:327-36. 35123660.
Medical subject headings
- COVID-19 Drug Treatment
- Extracorporeal Membrane Oxygenation